LJPC Key Stats
- After Hours Stock Movers 3/10 (LJPC) (POWR) (BYD) Higher; (FTEK) (AMZG) (URBN) Lower (more...) Street Insider 03/10 18:09 ET
- La Jolla Pharmaceutical (LJPC) Jumps 24% on Positive Trial Results Street Insider 03/10 17:30 ET
- Market Wrap: Chiquita Now Biggest Banana Brand; eBay Rejects Icahn Offer; McDonald's Comps Fell in Feb. Street Insider 03/10 17:19 ET
- La Jolla Pharma (LJPC) GCS-100 Phase 2 Met Primary, Secondary Endpoints Street Insider 03/10 16:16 ET
- La Jolla Pharmaceutical (LJPC) trading halted with news pending Street Insider 03/10 16:10 ET
- 5 Stocks Ready for Breakouts The Street 03/07 09:21 ET
- Let Price Action Be Your Guide The Street 03/06 11:35 ET
- UPDATE: Chardan Capital Markets Starts La Jolla Pharma (LJPC) at Buy, PT $32 Street Insider 03/06 10:43 ET
- Notable Analyst Rating Changes 03/06: (BIIB) (COG) (HA) Upgraded; (AUXL) (LOV) (ARTC) Downgraded Street Insider 03/06 10:34 ET
- La Jolla Pharma (LJPC) Expected to Present Positive Phase 2a GCS-100 Data Street Insider 03/06 09:30 ET
LJPC Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). La Jolla Pharmaceutical is up 129.5% over the last year vs S&P 500 Total Return up 24.21%, Biogen Idec up 96.08%, and Portola Pharmaceuticals up N/A.
Balance Sheet View Statement
Pro Ratings for LJPC
Pro Strategies Featuring LJPC
Did La Jolla Pharmaceutical make it into our Pro Portfolio Strategies?
Start your YCharts Pro membership now to find out.
- Sector: Healthcare
- Industry: Biotechnology
- Headquarters Country: United States
- Headquarters State/Province: California
- Incorporation Country: United States
- Incorporation State/Province: California
La Jolla Pharmaceutical Co. is a biopharmaceutical company engaged in the discovery, development and commercialization of therapeutics for chronic organ failure and cancer. It is engaged in the drug development of two products: GCS-100 and LJPC-501.